{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:23:20Z","timestamp":1787725400323,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"crossref","award":["013 Targeted Therapeutics Award 2013\u20132013;06)"],"award-info":[{"award-number":["013 Targeted Therapeutics Award 2013\u20132013;06)"]}],"id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Barry Neustein and Polyflex Corp.; Louis V. Gerstner, Jr. Scholar Award (SC); Lungevity Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung cancer has been the most common cancer worldwide for several decades. The outcomes of patients with locally advanced lung cancer remain dismal, and only a minority of patients survive more than 5\u00a0years. However, tumor therapeutic resistance mechanisms are poorly studied. Identification of therapeutic resistance pathways in lung cancer in order to increase the sensitivity of lung tumor cells to therapeutic agents is a crucial but challenging need. To identify novel genes that modulate the response to platinum-based therapy, we performed a genome-wide high-throughput ribonucleic acid interference (RNAi) screen via transfection of human lung cancer (PC9) cells with a viral short hairpin RNA (shRNA) library. We further validated a potential target via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and clonogenic survival assays on PC9 and A549 lung tumor cells transfected with small interfering RNAs (siRNAs) to successfully downregulate protein expression and then treated with increasing doses of cisplatin or X-ray radiation. We determined protein expression by immunohistochemistry (IHC) after chemoradiotherapy and analyzed gene expression-based survival outcomes in two cohorts of human non-small-cell lung cancer (NSCLC) patients. The screen identified several targets involved in epithelial-to-mesenchymal transition (EMT), including Smurf1, Smurf2, YAP1, and CEBPZ, and glycolytic pathway proteins, including PFKFB3. Furthermore, we found that the small molecule proteasome inhibitor bortezomib significantly downregulated Smurf2 in lung cancer cells. The addition of bortezomib in combination with cisplatin and radiation therapy in PC9 and A549 cells led to an increase in deoxyribonucleic acid (DNA) double-strand breaks with increased numbers of \u03b3-H2AX-positive cells and upregulation of apoptosis. Finally, we found that Smurf2 protein expression was upregulated in situ after treatment with cisplatin and radiation therapy in a relevant cohort of patients with stage III NSCLC. Additionally, Smurf2 gene expression was the strongest predictor of survival in patients with squamous NSCLC after chemotherapy or chemoradiotherapy. We successfully identified and validated Smurf2 as both a common modulator of resistance and an actionable target in lung cancer. These results suggest the urgent need to investigate clinical Smurf2 inhibition via bortezomib in combination with cisplatin and radiation for patients with locally advanced NSCLC.<\/jats:p>","DOI":"10.1038\/s41598-022-14448-8","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:35:56Z","timestamp":1655408156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Kunal R.","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Kinslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3629-4330","authenticated-orcid":false,"given":"Jiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony. J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom K.","family":"Hei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8360","authenticated-orcid":false,"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"14448_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584\u2013594. https:\/\/doi.org\/10.4065\/83.5.584 (2008).","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl 1","key":"14448_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.13-S1-5","volume":"13","author":"S Ramalingam","year":"2008","unstructured":"Ramalingam, S. & Belani, C. Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions. Oncologist 13(Suppl 1), 5\u201313. https:\/\/doi.org\/10.1634\/theoncologist.13-S1-5 (2008).","journal-title":"Oncologist"},{"issue":"10","key":"14448_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1200\/JCO.2013.53.7076","volume":"32","author":"JD Patel","year":"2014","unstructured":"Patel, J. D. et al. Clinical cancer advances 2013: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 32(10), 129\u2013160. https:\/\/doi.org\/10.1200\/JCO.2013.53.7076 (2014).","journal-title":"J. Clin. Oncol."},{"key":"14448_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/JTO.0b013e31824de2fa","volume":"7","author":"B Piperdi","year":"2012","unstructured":"Piperdi, B. et al. Phase-I\/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. 7, 1032\u20131040. https:\/\/doi.org\/10.1097\/JTO.0b013e31824de2fa (2012).","journal-title":"J. Thorac. Oncol."},{"key":"14448_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472\u2013476. https:\/\/doi.org\/10.1038\/nature15748 (2015).","journal-title":"Nature"},{"key":"14448_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"14448_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108, 153\u2013164 (2002).","journal-title":"Cell"},{"key":"14448_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.molcel.2013.01.017","volume":"49","author":"SP Jackson","year":"2013","unstructured":"Jackson, S. P. & Durocher, D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 49, 795\u2013807. https:\/\/doi.org\/10.1016\/j.molcel.2013.01.017 (2013).","journal-title":"Mol. Cell"},{"key":"14448_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S1097-2765(00)00134-9","volume":"6","author":"P Kavsak","year":"2000","unstructured":"Kavsak, P. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6, 1365\u20131375 (2000).","journal-title":"Mol. Cell"},{"key":"14448_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.bbcan.2012.11.003","volume":"119\u2013128","author":"D David","year":"1835","unstructured":"David, D., Nair, S. A. & Pillai, M. R. Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression. Biochim. Biophys. Acta 119\u2013128, 2013. https:\/\/doi.org\/10.1016\/j.bbcan.2012.11.003 (1835).","journal-title":"Biochim. Biophys. Acta"},{"key":"14448_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1073\/pnas.98.3.974","volume":"98","author":"Y Zhang","year":"2001","unstructured":"Zhang, Y., Chang, C., Gehling, D. J., Hemmati-Brivanlou, A. & Derynck, R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 98, 974\u2013979. https:\/\/doi.org\/10.1073\/pnas.98.3.974 (2001).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"14448_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/sj.onc.1207319","volume":"23","author":"H Li","year":"2004","unstructured":"Li, H. & Seth, A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 23, 1801\u20131808. https:\/\/doi.org\/10.1038\/sj.onc.1207319 (2004).","journal-title":"Oncogene"},{"key":"14448_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cell.2009.02.025","volume":"137","author":"M Narimatsu","year":"2009","unstructured":"Narimatsu, M. et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 137, 295\u2013307. https:\/\/doi.org\/10.1016\/j.cell.2009.02.025 (2009).","journal-title":"Cell"},{"key":"14448_CR14","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1101\/gad.1253004","volume":"18","author":"H Zhang","year":"2004","unstructured":"Zhang, H. & Cohen, S. N. Smurf2 up-regulation activates telomere-dependent senescence. Genes Dev. 18, 3028\u20133040. https:\/\/doi.org\/10.1101\/gad.1253004 (2004).","journal-title":"Genes Dev."},{"key":"14448_CR15","first-page":"7162","volume":"62","author":"M Fukuchi","year":"2002","unstructured":"Fukuchi, M. et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res. 62, 7162\u20137165 (2002).","journal-title":"Cancer Res."},{"key":"14448_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/0008-5472.CAN-08-1463","volume":"69","author":"C Jin","year":"2009","unstructured":"Jin, C. et al. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res. 69, 735\u2013740. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1463 (2009).","journal-title":"Cancer Res."},{"key":"14448_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nm.2596","volume":"18","author":"M Blank","year":"2012","unstructured":"Blank, M. et al. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat. Med. 18, 227\u2013234. https:\/\/doi.org\/10.1038\/nm.2596 (2012).","journal-title":"Nat. Med."},{"key":"14448_CR18","doi-asserted-by":"publisher","first-page":"28976","DOI":"10.18632\/oncotarget.6721","volume":"7","author":"H Cheng","year":"2016","unstructured":"Cheng, H. et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget 7, 28976\u201328988. https:\/\/doi.org\/10.18632\/oncotarget.6721 (2016).","journal-title":"Oncotarget"},{"key":"14448_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/ijo.2014.2545","volume":"45","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Bortezomib prevents oncogenesis and bone metastasis of 2 prostate cancer by inhibiting WWP1, Smurf1 and Smurf2. Int. J. Oncol. 45, 1469\u20131478. https:\/\/doi.org\/10.3892\/ijo.2014.2545 (2014).","journal-title":"Int. J. Oncol."},{"key":"14448_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","volume":"57","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G., Mitsiades, C., Hideshima, T. & Anderson, K. C. Bortezomib: 5 proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57, 33\u201347. https:\/\/doi.org\/10.1146\/annurev.med.57.042905.122625 (2006).","journal-title":"Annu. Rev. Med."},{"key":"14448_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.semradonc.2020.11.003","volume":"31","author":"A Wrona","year":"2021","unstructured":"Wrona, A. & Mornex, F. Hypofractionation in early stage non-small cell lung cancer. Semin. Radiat. Oncol. 31, 97\u2013104. https:\/\/doi.org\/10.1016\/j.semradonc.2020.11.003 (2021).","journal-title":"Semin. Radiat. Oncol."},{"key":"14448_CR22","doi-asserted-by":"publisher","DOI":"10.3791\/2597","author":"AM Rieger","year":"2011","unstructured":"Rieger, A. M., Nelson, K. L., Konowalchuk, J. D. & Barreda, D. R. Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death. J. Vis. Exp. https:\/\/doi.org\/10.3791\/2597 (2011).","journal-title":"J. Vis. Exp."},{"key":"14448_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"EA Collisson","year":"2014","unstructured":"Collisson, E. A. et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550. https:\/\/doi.org\/10.1038\/nature13385 (2014).","journal-title":"Nature"},{"key":"14448_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"PS Hammerman","year":"2012","unstructured":"Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u2013525. https:\/\/doi.org\/10.1038\/nature11404 (2012).","journal-title":"Nature"},{"key":"14448_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.cd-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0095 (2012).","journal-title":"Cancer Discov."},{"key":"14448_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"key":"14448_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052 (2018).","journal-title":"Cell"},{"key":"14448_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10637-013-0004-2","volume":"31","author":"SK Kumar","year":"2013","unstructured":"Kumar, S. K. et al. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest. New Drugs 31, 1201\u20131206. https:\/\/doi.org\/10.1007\/s10637-013-0004-2 (2013).","journal-title":"Invest. New Drugs"},{"key":"14448_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.athoracsur.2004.04.029","volume":"78","author":"CE Denlinger","year":"2004","unstructured":"Denlinger, C. E., Rundall, B. K., Keller, M. D. & Jones, D. R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann. Thorac. Surg. 78, 1207\u20131214. https:\/\/doi.org\/10.1016\/j.athoracsur.2004.04.029 (2004) (Discussion 1207\u20131214).","journal-title":"Ann. Thorac. Surg."},{"key":"14448_CR30","doi-asserted-by":"publisher","first-page":"s4647","DOI":"10.1158\/1078-0432.CCR-07-0334","volume":"13","author":"AM Davies","year":"2007","unstructured":"Davies, A. M., Lara, P. N. Jr., Mack, P. C. & Gandara, D. R. Incorporating bortezomib into the treatment of lung cancer. Clin. Cancer Res. 13, s4647-4651. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0334 (2007).","journal-title":"Clin. Cancer Res."},{"key":"14448_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1593\/tlo.12229","volume":"5","author":"D Wei","year":"2012","unstructured":"Wei, D., Morgan, M. A. & Sun, Y. Radiosensitization of cancer cells by inactivation of Cullin-RING E3 ubiquitin ligases. Transl. Oncol. 5, 305\u2013312 (2012).","journal-title":"Transl. Oncol."},{"key":"14448_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.exphem.2005.04.005","volume":"33","author":"A Goel","year":"2005","unstructured":"Goel, A. et al. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp. Hematol. 33, 784\u2013795. https:\/\/doi.org\/10.1016\/j.exphem.2005.04.005 (2005).","journal-title":"Exp. Hematol."},{"key":"14448_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0360-3016(01)01446-8","volume":"50","author":"SM Russo","year":"2001","unstructured":"Russo, S. M. et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183\u2013193 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"14448_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2009.12.002","volume":"293","author":"WK Wu","year":"2010","unstructured":"Wu, W. K. et al. Proteasome inhibition: A new therapeutic strategy to cancer treatment. Cancer Lett. 293, 15\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2009.12.002 (2010).","journal-title":"Cancer Lett."},{"key":"14448_CR35","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 6.2020 edn, Vol. 2020 (Nationaly Comprehensive Cancer Network, 2020)."},{"key":"14448_CR36","doi-asserted-by":"publisher","first-page":"22818","DOI":"10.1074\/jbc.M110.126920","volume":"285","author":"J Nie","year":"2010","unstructured":"Nie, J. et al. Smad ubiquitylation regulatory factor 1\/2 (Smurf1\/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J. Biol. Chem. 285, 22818\u201322830. https:\/\/doi.org\/10.1074\/jbc.M110.126920 (2010).","journal-title":"J. Biol. Chem."},{"key":"14448_CR37","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1073\/pnas.2627983100","volume":"100","author":"H Zhang","year":"2003","unstructured":"Zhang, H., Pan, K. H. & Cohen, S. N. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc. Natl. Acad. Sci. U.S.A. 100, 3251\u20133256. https:\/\/doi.org\/10.1073\/pnas.2627983100 (2003).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"14448_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jnci\/djs471","volume":"105","author":"MP Smith","year":"2013","unstructured":"Smith, M. P. et al. Effect of Smurf2 targeting on susceptibility to MEK inhibitors in melanoma. J. Natl. Cancer Inst. 105, 33\u201346. https:\/\/doi.org\/10.1093\/jnci\/djs471 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"14448_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2009.05.003","volume":"68","author":"MJ Edelman","year":"2010","unstructured":"Edelman, M. J. et al. Phase I trial of carboplatin\/paclitaxel\/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung Cancer 68, 84\u201388. https:\/\/doi.org\/10.1016\/j.lungcan.2009.05.003 (2010).","journal-title":"Lung Cancer"},{"key":"14448_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/JTO.0000000000000383","volume":"10","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. A phase I\/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J. Thorac. Oncol. 10, 172\u2013180. https:\/\/doi.org\/10.1097\/JTO.0000000000000383 (2015).","journal-title":"J. Thorac. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14448-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14448-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14448-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:14:58Z","timestamp":1669353298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14448-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14448"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14448-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10140"}}